Veru (NASDAQ:VERU) Receives “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Veru (NASDAQ:VERU) in a report issued on Thursday,Benzinga reports. HC Wainwright currently has a $3.00 target price on the stock.

Separately, Oppenheimer reaffirmed an “outperform” rating and issued a $5.00 price target on shares of Veru in a research note on Tuesday, November 5th.

Veru Stock Up 0.2 %

VERU opened at $0.65 on Thursday. The firm’s fifty day simple moving average is $0.70 and its two-hundred day simple moving average is $0.80. Veru has a 52-week low of $0.36 and a 52-week high of $1.92. The company has a market cap of $95.41 million, a price-to-earnings ratio of -1.36 and a beta of -0.50.

Veru (NASDAQ:VERU) last issued its quarterly earnings results on Monday, December 16th. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01. Veru had a negative net margin of 376.38% and a negative return on equity of 115.99%. On average, research analysts forecast that Veru will post -0.3 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of VERU. Bank of New York Mellon Corp raised its stake in Veru by 1,718.2% during the second quarter. Bank of New York Mellon Corp now owns 443,782 shares of the company’s stock worth $373,000 after purchasing an additional 419,374 shares during the period. Rhumbline Advisers increased its holdings in shares of Veru by 3,994.8% during the 2nd quarter. Rhumbline Advisers now owns 113,632 shares of the company’s stock worth $96,000 after buying an additional 110,857 shares during the last quarter. Choreo LLC raised its position in shares of Veru by 261.3% during the 2nd quarter. Choreo LLC now owns 332,050 shares of the company’s stock valued at $292,000 after buying an additional 240,134 shares during the period. Blair William & Co. IL lifted its holdings in Veru by 6.1% in the second quarter. Blair William & Co. IL now owns 350,000 shares of the company’s stock valued at $294,000 after acquiring an additional 20,000 shares during the last quarter. Finally, Squarepoint Ops LLC purchased a new position in Veru in the second quarter worth approximately $161,000. Institutional investors and hedge funds own 47.16% of the company’s stock.

About Veru

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.